ALESI_SURGICAL_LIMITED - Accounts


Company Registration No. 06133243 (England and Wales)
ALESI SURGICAL LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017
PAGES FOR FILING WITH REGISTRAR
ALESI SURGICAL LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 15
ALESI SURGICAL LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2017
31 December 2017
- 1 -
2017
2016
as restated
Notes
£
£
£
£
Fixed assets
Intangible assets
4
785,333
321,121
Tangible assets
5
46,361
54,411
Investments
6
76
-
831,770
375,532
Current assets
Stocks
251,118
317,393
Debtors
8
242,484
75,069
Cash at bank and in hand
3,353,640
131,653
3,847,242
524,115
Creditors: amounts falling due within one year
9
(318,711)
(244,420)
Net current assets
3,528,531
279,695
Total assets less current liabilities
4,360,301
655,227
Creditors: amounts falling due after more than one year
10
(30,164)
(29,411)
Net assets
4,330,137
625,816
Capital and reserves
Called up share capital
11
10,509
5,896
Share premium account
11,151,492
5,993,626
Profit and loss reserves
(6,831,864)
(5,373,706)
Total equity
4,330,137
625,816

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

ALESI SURGICAL LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 DECEMBER 2017
31 December 2017
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 17 July 2018 and are signed on its behalf by:
Dr D J F Griffiths
Director
Company Registration No. 06133243
ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017
- 3 -
1
Accounting policies
Company information

Alesi Surgical Limited is a private company limited by shares incorporated in England and Wales. The registered office is Cardiff Medicentre, Heath Park, CARDIFF, UK, CF14 4UJ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

These financial statements for the year ended 31 December 2017 are the first financial statements of Alesi Surgical Limited prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 August 2015. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.

1.2
Going concern

Cash flow forecasts prepared for a period of 12 months from the date of approval of the financial statements indicate that the Company can continue to operate within its available working capital facilities. These forecasts have been prepared on the assumption that the Shareholders will continue to support the Company to meet its working capital requirements as necessary.

At 31 December 2017 the company held cash balances of £3,353,640. The had sufficient resources to meet its non-discretionary liabilities for a period not less than 12 months from the approval of the financial statements.

 

The Directors have a reasonable expectation that the company will have adequate resources to continue in operation and existence for the foreseeable future. For these reasons, they continue to adopt the going concern basis in preparing the financial statements and the financial statements do not include any adjustments that would result from the basis of the preparation being inappropriate.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.4
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
1
Accounting policies (Continued)
- 4 -
1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the cost or value of the asset can be measured reliably.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents & licences
10% straight line
Development costs
10% straight line
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
20% - 33% straight line
Computer equipment
33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.8
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
1
Accounting policies (Continued)
- 5 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.9
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.10
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.11
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
1
Accounting policies (Continued)
- 6 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.12
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.13
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
1
Accounting policies (Continued)
- 7 -
1.14
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.16
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease asset are consumed.

Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.

1.17
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2
Change in accounting policy

In the current year, the following new and revised Standards and Interpretations have been adopted by the company and have an effect on the current period or a prior period or may have an effect on future periods:

Patent and development costs had been previously treated as revenue expenditure and the policy has now been changed to capitalise these costs where appropriately. For more information on the prior period adjustment please refer to note 14.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was 11 (2016 - 10).

ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 8 -
4
Intangible fixed assets
Other
£
Cost
At 1 January 2017
321,121
Additions
496,324
At 31 December 2017
817,445
Amortisation and impairment
At 1 January 2017
-
Amortisation charged for the year
32,112
At 31 December 2017
32,112
Carrying amount
At 31 December 2017
785,333
At 31 December 2016
321,121
5
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2017
83,186
Additions
2,309
Transfers
10,602
At 31 December 2017
96,097
Depreciation and impairment
At 1 January 2017
28,775
Depreciation charged in the year
20,961
At 31 December 2017
49,736
Carrying amount
At 31 December 2017
46,361
At 31 December 2016
54,411
6
Fixed asset investments
2017
2016
£
£
Investments
76
-
ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
6
Fixed asset investments (Continued)
- 9 -
Movements in fixed asset investments
Shares in group undertakings
£
Cost or valuation
At 1 January 2017
-
Valuation changes
76
At 31 December 2017
76
Carrying amount
At 31 December 2017
76
At 31 December 2016
-
7
Subsidiaries

Details of the company's subsidiaries at 31 December 2017 are as follows:

Name of undertaking
Registered
Nature of business
Class of
% Held
office
shares held
Direct
Indirect
Alesi Surgical Technologies Inc.
USA
Medical devices
Ordinary
100.00
The aggregate capital and reserves and the result for the year of the subsidiaries noted above was as follows:
Name of undertaking
Profit/(Loss)
Capital and Reserves
£
£
Alesi Surgical Technologies Inc.
(142,537)
(142,461)
8
Debtors
2017
2016
Amounts falling due within one year:
£
£
Trade debtors
14,800
15,997
Amounts owed by group undertakings
154,902
-
Other debtors
72,782
59,072
242,484
75,069
ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 10 -
9
Creditors: amounts falling due within one year
2017
2016
£
£
Trade creditors
182,753
77,513
Other taxation and social security
16,554
20,504
Other creditors
119,404
146,403
318,711
244,420
10
Creditors: amounts falling due after more than one year
2017
2016
£
£
Other creditors
30,164
29,411
ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 11 -
11
Called up share capital
2017
2016
£
£
Ordinary share capital
Issued and fully paid
1,053Ordinary shares of £1 each
1,053
1,052
2,200Ordinary B shares of 1p each
22
22
1,075
1,074
Preference share capital
Issued and fully paid
4,822Preferred A shares of £1 each
4,822
4,822
4,612Preferred B shares of £1 each
4,612
-
9,434
4,822
ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
11
Called up share capital (Continued)
- 12 -

On 2nd March 2017 the company issued 1 Ordinary share at £1 per share. Total consideration received in relation to the share issue was £19,040.

 

On 2nd March 2017 the company issued 2,678 Preferred B shares at £1 per share. Total consideration received in relation to the share issue was £2,995,280.

 

On 22nd May 2017 the company issued 1,918 Preferred B shares at £1 per share. Total consideration received in relation to the share issue was £2,148,160.

 

On 22nd May 2017 the company transferred 16 Ordinary shares of £1 each to 16 Preferred B shares of £1 each. No further consideration was received in relation to this transfer.

 

2010 Option Scheme

On 10 September 2010 the company granted 1 non employee and 1 employee options over a total of 65 Ordinary Shares at an exercise price of £1.00 per share. 65 of these share options have been vested.

 

2012 Option Scheme

On 22 June 2012 the company granted 1 non employee and 2 employees options over a total of 40 Ordinary Shares at an exercise price of £519.62 per share. 40 of these share options have been vested.

 

2013 Option Scheme

On 24 January 2013 the company granted employee options over a total of 175 Ordinary shares at an exercise price of £646.07 per share. 175 of these share options have been vested.

 

2014 Option Scheme

On 20 May 2014 the company granted 2 employees options over a total of 175 Ordinary shares at an exercise price of £646.07 per share. 175 of these share options have been vested.

 

2016 Option Scheme

On 22 January 2016 the company granted 4 employee options over a total of 222 Ordinary shares at an exercise price of £646.07 per share. 222 of these share options have been vested.

 

2017 Option Schemes

On 20 July 2017 the company granted 9 employees options over a total of 608 Ordinary shares at an exercise price of £1.00 per share. 608 of these share options have been vested.

 

On 22 December 2017 the company granted 1 employee option over a total of 100 Ordinary shares at an exercise price of £224.00 per share. 100 of these share options have been vested.

 

 

 

 

12
Audit report information

As the income statement has been omitted from the filing copy of the financial statements the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

The senior statutory auditor was Laura Farrow MSc BSc FCA.
The auditor was MHA Broomfield Alexander.
ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 13 -
13
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2017
2016
£
£
17,080
37,458
ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
- 14 -
14
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

Sale of goods
Purchase of goods
2017
2016
2017
2016
£
£
£
£
Entities with control, joint control or significant influence over the company
12,568
-
168,607
142,869

The following amounts were outstanding at the reporting end date:

2017
2016
Amounts owed to related parties
£
£
Entities over which the entity has control, joint control or significant influence
1,015
4,606

The following amounts were outstanding at the reporting end date:

2017
Balance
Amounts owed by related parties
£
Entities over which the entity has control, joint control or significant influence
154,978
There were no amounts owed in the previous period.
15
Prior period adjustment
Reconciliation of changes in equity
1 January
31 December
2016
2016
Notes
£
£
Equity as previously reported
2,164,899
304,695
Adjustments to prior year
Intangible fixed assets
3
-
321,121
Equity as adjusted
2,164,899
625,816
ALESI SURGICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2017
15
Prior period adjustment (Continued)
- 15 -
Reconciliation of changes in loss for the previous financial period
2016
Notes
£
Loss as previously reported
(1,860,204)
Adjustments to prior year
Intangible fixed assets
3
321,121
Loss as adjusted
(1,539,083)
Notes to reconciliation

The financial statements for 2016 have been re-stated by £321,121 being costs previously expensed now capitalised as an intangible fixed asset. This represents a change in accounting policy.

 

Previously the company accounted for patent and development costs as revenue expenditure. The new policy is to capitalise the appropriate patent and development costs in the year of purchase and to amortise these costs over a ten year period commencing in the first full accounting period after occurring the expenditure.

2017-12-312017-01-01falseCCH SoftwareCCH Accounts Production 2018.220No description of principal activity23 July 2018This audit opinion is unqualifiedMr D C FrederickDr D J F GriffithsMr P M CooperEarlybird Health Tech GMBHIP2IPO Services LimitedPanakes Partners SGR SPADr P L GrantMr T E RascheMr N Warren061332432017-01-012017-12-31061332432017-12-31061332432016-12-3106133243core:IntangibleAssetsOtherThanGoodwill2017-12-3106133243core:IntangibleAssetsOtherThanGoodwill2016-12-3106133243core:OtherPropertyPlantEquipment2017-12-3106133243core:OtherPropertyPlantEquipment2016-12-3106133243core:CurrentFinancialInstruments2017-12-3106133243core:CurrentFinancialInstruments2016-12-3106133243core:Non-currentFinancialInstruments2017-12-3106133243core:Non-currentFinancialInstruments2016-12-3106133243core:ShareCapital2017-12-3106133243core:ShareCapital2016-12-3106133243core:SharePremium2017-12-3106133243core:SharePremium2016-12-3106133243core:RetainedEarningsAccumulatedLosses2017-12-3106133243core:RetainedEarningsAccumulatedLosses2016-12-3106133243core:ShareCapitalOrdinaryShares2017-12-3106133243core:ShareCapitalOrdinaryShares2016-12-3106133243core:ShareCapitalPreferenceShares2017-12-3106133243core:ShareCapitalPreferenceShares2016-12-3106133243bus:Director22017-01-012017-12-3106133243core:PlantMachinery2017-01-012017-12-3106133243core:ComputerEquipment2017-01-012017-12-3106133243core:IntangibleAssetsOtherThanGoodwill2016-12-3106133243core:IntangibleAssetsOtherThanGoodwill2017-01-012017-12-3106133243core:OtherPropertyPlantEquipment2016-12-3106133243core:OtherPropertyPlantEquipment2017-01-012017-12-3106133243core:Subsidiary12017-01-012017-12-3106133243core:Subsidiary112017-01-012017-12-3106133243core:Subsidiary122017-01-012017-12-3106133243bus:OrdinaryShareClass12017-01-012017-12-3106133243bus:OrdinaryShareClass22017-01-012017-12-3106133243bus:PreferenceShareClass12017-01-012017-12-3106133243bus:PreferenceShareClass22017-01-012017-12-3106133243bus:OrdinaryShareClass12017-12-3106133243bus:OrdinaryShareClass22017-12-3106133243bus:PreferenceShareClass12017-12-3106133243bus:PreferenceShareClass22017-12-3106133243bus:PrivateLimitedCompanyLtd2017-01-012017-12-3106133243bus:FRS1022017-01-012017-12-3106133243bus:Audited2017-01-012017-12-3106133243bus:SmallCompaniesRegimeForAccounts2017-01-012017-12-3106133243bus:Director12017-01-012017-12-3106133243bus:Director32017-01-012017-12-3106133243bus:Director42017-01-012017-12-3106133243bus:Director52017-01-012017-12-3106133243bus:Director62017-01-012017-12-3106133243bus:Director72017-01-012017-12-3106133243bus:Director82017-01-012017-12-3106133243bus:Director92017-01-012017-12-3106133243bus:FullAccounts2017-01-012017-12-31xbrli:purexbrli:sharesiso4217:GBP